Shore, Neal

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchImmunotherapy and Immune Responses

Cited by 5,572

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 4,586

Olaparib for Metastatic Castration-Resistant Prostate Cancer

de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,323

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 1,369

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 930

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 792

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., et al. (2023) · The Lancet

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 538

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., De Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., et al. (2020) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 428

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., et al. (2022) · NEJM Evidence

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 426

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 362

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 326

Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer

Fizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Shore, N., Oudard, S., Karsh, L., Carducci, M., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 142

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 130

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

Petrylak, D. P., Kantoff, P., Vogelzang, N. J., Mega, A., Fleming, M. T., Stephenson, J. J., Frank, R., Shore, N. D., Dreicer, R., McClay, E. F., et al. (2019) · The Prostate

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 84

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Sartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 71

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302

Saad, F., Shore, N., Van Poppel, H., Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., de Souza, P., Fizazi, K., Mulders, P. F. A., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 63

Real-World Genetic Testing Patterns in Metastatic Castration-Resistant Prostate Cancer

Shore, N., Ionescu-Ittu, R., Yang, L., Laliberté, F., Mahendran, M., Lejeune, D., Yu, L., Burgents, J., Duh, M. S., & Ghate, S. R. (2021) · Future Oncology

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 36

Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey

McManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 32

A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).

Petrylak, D. P., Vogelzang, N. J., Chatta, G. S., Fleming, M. T., Smith, D. C., Appleman, L. J., Hussain, A., Modiano, M., Singh, P., Tagawa, S. T., et al. (2015) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 25

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 17

Epidemiology and O-Serotypes of Extraintestinal Pathogenic Escherichia coli Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study

Rosenberg, S., Bonten, M., Haazen, W., Spiessens, B., Abbanat, D., Go, O., Wagenlehner, F., Shore, N., Hagiwara, Y., Ibarra de Palacios, P., et al. (2021) · Journal of Urology

Escherichia coli research studiesUrinary Tract Infections Management

Cited by 13

Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)

Iyer, G., Siefker-Radtke, A., Milowsky, M., Shore, N., Gao, X., Reimers, M. A., Hahn, N., Cosman, R., Matsubara, N., Necchi, A., et al. (2023) · Cancer Research

Fibroblast Growth Factor ResearchLung Cancer Treatments and Mutations

Cited by 12